A use of loganin to treat spinal muscular atrophy is disclosed. The loganin is supplied to manufacture a medical product for treating the spinal muscular atrophy. The spinal muscular atrophy is at least one of a first type spinal muscular atrophy, a second type spinal muscular atrophy and a third type spinal muscular atrophy. The medical product includes a pharmacy acceptable carrier agent. The pharmacy acceptable carrier agent includes at least one test agent selected from the group consisting of solvent, buffer, suspending agent, decomposer, disintegrating agent, dispersing agent, binding agent, excipient, stabilizing agent, chelating agent, diluent, gelling agent, preservative, lubricant, absorption delaying agent and liposome.本發明揭示馬錢子苷可被用來治療脊髓性肌肉萎縮症。
